C4 Therapeutics Key Executives
This section highlights C4 Therapeutics's key executives, including their titles and compensation details.
Find Contacts at C4 Therapeutics
(Showing 0 of )
C4 Therapeutics Earnings
This section highlights C4 Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
$1.54
Stock Price
$109.35M
Market Cap
110
Employees
Watertown, MA
Location
Financial Statements
Access annual & quarterly financial statements for C4 Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $35.58M | $20.76M | $31.10M | $45.78M | $33.20M |
| Cost of Revenue | $- | $117.71M | $7.57M | $2.91M | $77.47M |
| Gross Profit | $35.58M | $-96.95M | $23.52M | $42.88M | $-44.27M |
| Gross Profit Ratio | 100.00% | -467.09% | 75.65% | 93.65% | -133.37% |
| Research and Development Expenses | $110.64M | $117.71M | $117.84M | $94.67M | $78.44M |
| General and Administrative Expenses | $42.12M | $42.08M | $42.79M | $33.25M | $15.20M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $42.12M | $42.08M | $42.79M | $33.25M | $15.20M |
| Other Expenses | $2.44M | $- | $- | $- | $- |
| Operating Expenses | $155.20M | $159.79M | $160.63M | $127.92M | $93.64M |
| Cost and Expenses | $155.20M | $159.79M | $160.63M | $127.92M | $93.64M |
| Interest Income | $14.43M | $9.81M | $3.58M | $387.00K | $393.00K |
| Interest Expense | $- | $1.37M | $2.22M | $2.15M | $1.23M |
| Depreciation and Amortization | $1.82M | $7.74M | $7.57M | $2.91M | $2.84M |
| EBITDA | $-103.37M | $-122.10M | $-124.28M | $-78.84M | $-62.89M |
| EBITDA Ratio | -290.49% | -588.28% | -399.68% | -172.20% | -189.46% |
| Operating Income | $-119.61M | $-139.03M | $-129.53M | $-82.13M | $-60.45M |
| Operating Income Ratio | -336.15% | -669.84% | -416.56% | -179.39% | -182.10% |
| Total Other Income Expenses Net | $14.43M | $7.82M | $1.36M | $-1.76M | $-6.51M |
| Income Before Tax | $-105.19M | $-131.21M | $-128.18M | $-83.89M | $-66.96M |
| Income Before Tax Ratio | -295.60% | -632.17% | -412.19% | -183.23% | -201.72% |
| Income Tax Expense | $131.00K | $1.28M | $-1.68M | $2.15M | $-626.00K |
| Net Income | $-105.32M | $-132.49M | $-126.50M | $-86.04M | $-66.33M |
| Net Income Ratio | -295.96% | -638.34% | -406.80% | -187.92% | -199.83% |
| EPS | $-1.52 | $-2.67 | $-2.59 | $-1.87 | $-1.54 |
| EPS Diluted | $-1.52 | $-2.67 | $-2.59 | $-1.87 | $-1.54 |
| Weighted Average Shares Outstanding | 69.37M | 49.64M | 48.86M | 46.04M | 43.06M |
| Weighted Average Shares Outstanding Diluted | 69.37M | 49.64M | 48.86M | 46.04M | 43.06M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.18M | $15.36M | $12.01M | $3.04M | $3.26M | $11.07M | $2.66M | $3.76M | $2.85M | $6.75M | $13.83M | $7.65M | $20.08M | $8.50M | $9.78M | $7.43M | $8.26M | $8.45M | $9.67M | $6.82M |
| Cost of Revenue | $- | $2.06M | $2.04M | $2.03M | $1.69M | $2.00M | $1.99M | $2.06M | $2.02M | $1.92M | $2.14M | $1.49M | $758.00K | $24.30M | $23.29M | $20.53M | $19.46M | $23.93M | $17.76M | $16.31M |
| Gross Profit | $5.18M | $13.31M | $9.96M | $1.01M | $1.57M | $9.08M | $675.00K | $1.70M | $831.00K | $4.83M | $11.69M | $6.17M | $19.32M | $-15.80M | $-13.51M | $-13.10M | $-11.20M | $-15.49M | $-8.09M | $-9.50M |
| Gross Profit Ratio | 100.00% | 86.62% | 82.97% | 33.30% | 48.14% | 81.98% | 25.34% | 45.15% | 29.12% | 71.59% | 84.52% | 80.55% | 96.22% | -185.91% | -138.07% | -176.41% | -135.55% | -183.36% | -83.66% | -139.32% |
| Research and Development Expenses | $32.51M | $31.84M | $23.75M | $22.53M | $30.39M | $28.35M | $29.93M | $29.04M | $30.65M | $29.66M | $31.32M | $26.20M | $26.55M | $24.30M | $23.29M | $20.53M | $20.43M | $23.93M | $17.76M | $16.31M |
| General and Administrative Expenses | $10.37M | $11.77M | $9.70M | $10.29M | $10.30M | $10.53M | $10.31M | $10.95M | $10.49M | $9.58M | $9.89M | $12.82M | $8.78M | $8.45M | $8.61M | $7.41M | $6.73M | $2.86M | $2.77M | $2.84M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $-1.69M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $10.37M | $11.77M | $9.70M | $10.29M | $8.61M | $10.53M | $10.31M | $10.95M | $10.49M | $9.58M | $9.89M | $12.82M | $8.78M | $8.45M | $8.61M | $7.41M | $6.73M | $2.86M | $2.77M | $2.84M |
| Other Expenses | $- | $- | $- | $2.44M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $43.00K | $- | $- |
| Operating Expenses | $42.89M | $43.61M | $33.45M | $35.26M | $39.00M | $38.88M | $40.23M | $39.99M | $41.15M | $39.24M | $41.22M | $39.02M | $35.33M | $32.75M | $31.90M | $27.93M | $27.16M | $26.80M | $20.53M | $19.15M |
| Cost and Expenses | $42.89M | $43.61M | $33.45M | $35.26M | $40.69M | $38.88M | $40.23M | $39.99M | $41.15M | $39.24M | $41.22M | $39.02M | $35.33M | $32.75M | $31.90M | $27.93M | $27.16M | $26.80M | $20.53M | $19.15M |
| Interest Income | $3.27M | $3.58M | $3.73M | $3.86M | $2.95M | $2.56M | $2.25M | $2.05M | $1.71M | $1.08M | $506.00K | $276.00K | $136.00K | $110.00K | $69.00K | $72.00K | $576.00K | $50.00K | $25.00K | $259.00K |
| Interest Expense | $- | $- | $- | $- | $- | $167.00K | $600.00K | $606.00K | $601.00K | $554.00K | $534.00K | $527.00K | $539.00K | $539.00K | $533.00K | $534.00K | $1.06M | $352.00K | $127.00K | $- |
| Depreciation and Amortization | $480.00K | $2.06M | $2.04M | $2.03M | $1.69M | $2.00M | $1.99M | $2.06M | $2.02M | $1.92M | $2.14M | $1.49M | $758.00K | $663.00K | $715.00K | $771.00K | $365.00K | $420.00K | $416.00K | $416.00K |
| EBITDA | $-33.96M | $-22.61M | $-15.67M | $-26.33M | $-32.79M | $-23.87M | $-33.33M | $-32.11M | $-34.56M | $-29.48M | $-24.74M | $-29.60M | $-14.36M | $-23.81M | $-21.33M | $-19.67M | $-20.41M | $-20.72M | $-10.44M | $-11.66M |
| EBITDA Ratio | -656.02% | -147.18% | -130.53% | -866.54% | -1005.40% | -215.61% | -1251.24% | -854.27% | -1210.97% | -436.56% | -178.81% | -386.78% | -71.53% | -280.16% | -218.10% | -264.83% | -247.03% | -245.26% | -107.99% | -171.11% |
| Operating Income | $-37.71M | $-28.24M | $-21.44M | $-32.22M | $-37.43M | $-27.81M | $-37.57M | $-36.23M | $-38.29M | $-32.49M | $-27.38M | $-31.37M | $-15.26M | $-24.25M | $-22.12M | $-20.51M | $-18.90M | $-18.35M | $-10.86M | $-12.34M |
| Operating Income Ratio | -728.39% | -183.86% | -178.59% | -1060.18% | -1147.72% | -251.16% | -1410.21% | -963.77% | -1341.73% | -481.02% | -197.95% | -409.84% | -75.98% | -285.34% | -226.11% | -276.18% | -228.79% | -217.23% | -112.30% | -181.02% |
| Total Other Income Expenses Net | $3.27M | $3.58M | $3.73M | $1.42M | $2.95M | $1.77M | $1.65M | $1.45M | $1.11M | $530.00K | $-28.00K | $-251.00K | $-403.00K | $-429.00K | $-464.00K | $-462.00K | $-3.02M | $-3.65M | $-102.00K | $259.00K |
| Income Before Tax | $-34.44M | $-24.67M | $-17.72M | $-28.36M | $-34.48M | $-26.03M | $-35.92M | $-34.78M | $-37.19M | $-31.96M | $-27.41M | $-31.62M | $-15.66M | $-24.68M | $-22.58M | $-20.97M | $-21.92M | $-22.00M | $-10.96M | $-12.08M |
| Income Before Tax Ratio | -665.29% | -160.57% | -147.56% | -933.23% | -1057.25% | -235.13% | -1348.42% | -925.25% | -1302.91% | -473.17% | -198.15% | -413.12% | -77.99% | -290.39% | -230.86% | -282.40% | -265.30% | -260.47% | -113.35% | -177.22% |
| Income Tax Expense | $131.00K | $- | $-2.04M | $-2.03M | $277.00K | $-1.00M | $1.79M | $-842.00K | $-1.11M | $-530.00K | $28.00K | $251.00K | $539.00K | $110.00K | $69.00K | $72.00K | $-124.00K | $-167.00K | $-168.00K | $-167.00K |
| Net Income | $-34.57M | $-24.67M | $-17.72M | $-28.36M | $-34.75M | $-27.04M | $-35.92M | $-33.94M | $-36.08M | $-31.43M | $-27.44M | $-31.87M | $-15.66M | $-24.68M | $-22.58M | $-20.97M | $-21.80M | $-21.84M | $-10.79M | $-11.91M |
| Net Income Ratio | -667.82% | -160.57% | -147.56% | -933.23% | -1065.75% | -244.19% | -1348.42% | -902.85% | -1264.09% | -465.32% | -198.35% | -416.40% | -77.99% | -290.39% | -230.86% | -282.40% | -263.80% | -258.49% | -111.61% | -174.77% |
| EPS | $-0.49 | $-0.35 | $-0.26 | $-0.41 | $-0.68 | $-0.55 | $-0.73 | $-0.69 | $-0.74 | $-0.64 | $-0.56 | $-0.66 | $-0.32 | $-0.51 | $-0.51 | $-0.49 | $-0.53 | $-0.54 | $-0.26 | $-0.69 |
| EPS Diluted | $-0.49 | $-0.35 | $-0.26 | $-0.41 | $-0.68 | $-0.55 | $-0.73 | $-0.69 | $-0.74 | $-0.64 | $-0.56 | $-0.65 | $-0.32 | $-0.51 | $-0.51 | $-0.49 | $-0.53 | $-0.54 | $-0.26 | $-0.69 |
| Weighted Average Shares Outstanding | 70.61M | 69.63M | 68.81M | 68.43M | 51.22M | 49.21M | 49.06M | 49.03M | 48.97M | 48.92M | 48.82M | 48.65M | 48.49M | 48.49M | 43.86M | 43.08M | 40.77M | 40.77M | 40.77M | 17.23M |
| Weighted Average Shares Outstanding Diluted | 70.61M | 69.63M | 68.81M | 68.43M | 51.22M | 49.21M | 49.06M | 49.03M | 48.97M | 48.92M | 48.82M | 48.73M | 48.49M | 48.49M | 43.86M | 43.08M | 40.77M | 40.77M | 40.77M | 17.23M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $55.50M | $126.59M | $29.75M | $76.12M | $181.73M |
| Short Term Investments | $189.41M | $127.09M | $246.40M | $233.16M | $189.96M |
| Cash and Short Term Investments | $244.90M | $253.68M | $337.12M | $309.28M | $371.69M |
| Net Receivables | $3.10M | $11.80M | $1.47M | $5.72M | $4.48M |
| Inventory | $- | $- | $-60.96M | $- | $- |
| Other Current Assets | $9.76M | $5.71M | $9.93M | $21.39M | $9.67M |
| Total Current Assets | $257.77M | $271.19M | $287.56M | $325.69M | $381.01M |
| Property Plant Equipment Net | $63.38M | $71.09M | $77.52M | $35.05M | $16.55M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $22.36M | $28.01M | $60.96M | $142.20M | $2.58M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $6.10M | $6.17M | $4.80M | $3.82M | $- |
| Total Non-Current Assets | $91.83M | $105.26M | $143.28M | $181.08M | $19.13M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $349.60M | $376.45M | $430.84M | $506.76M | $400.14M |
| Account Payables | $1.33M | $1.45M | $1.17M | $4.51M | $5.68M |
| Short Term Debt | $5.77M | $5.22M | $11.69M | $2.67M | $2.08M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $18.71M | $15.47M | $33.51M | $31.80M | $27.60M |
| Other Current Liabilities | $19.36M | $20.63M | $15.07M | $12.27M | $8.48M |
| Total Current Liabilities | $45.18M | $42.77M | $44.55M | $51.25M | $43.85M |
| Long Term Debt | $59.98M | $65.76M | $80.17M | $72.32M | $33.70M |
| Deferred Revenue Non-Current | $28.46M | $21.81M | $16.89M | $24.37M | $53.62M |
| Deferred Tax Liabilities Non-Current | $- | $- | $9.20M | $10.77M | $10.05M |
| Other Non-Current Liabilities | $- | $- | $- | $-30.78M | $-11.83M |
| Total Non-Current Liabilities | $88.44M | $87.57M | $97.06M | $65.91M | $75.50M |
| Other Liabilities | $- | $-1 | $- | $- | $- |
| Total Liabilities | $133.62M | $130.34M | $141.61M | $117.16M | $119.35M |
| Preferred Stock | $- | $- | $- | $- | $400.14M |
| Common Stock | $7.00K | $6.00K | $5.00K | $5.00K | $4.00K |
| Retained Earnings | $-633.70M | $-528.38M | $-395.89M | $-267.71M | $-183.82M |
| Accumulated Other Comprehensive Income Loss | $53.00K | $-127.00K | $-4.14M | $-775.00K | $13.00K |
| Other Total Stockholders Equity | $849.62M | $774.62M | $689.26M | $658.09M | $464.60M |
| Total Stockholders Equity | $215.99M | $246.11M | $289.23M | $389.61M | $280.79M |
| Total Equity | $215.99M | $246.11M | $289.23M | $389.61M | $280.79M |
| Total Liabilities and Stockholders Equity | $349.60M | $376.45M | $430.84M | $506.76M | $400.14M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $349.60M | $376.45M | $430.84M | $506.76M | $400.14M |
| Total Investments | $211.76M | $155.10M | $307.36M | $375.36M | $189.96M |
| Total Debt | $65.76M | $70.98M | $87.15M | $42.88M | $22.92M |
| Net Debt | $10.26M | $-55.61M | $57.40M | $-33.24M | $-158.81M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $55.50M | $59.65M | $73.11M | $89.66M | $126.59M | $60.97M | $44.88M | $49.48M | $29.75M | $49.55M | $57.30M | $46.00M | $76.12M | $162.75M | $281.15M | $94.91M | $181.73M | $63.43M | $112.15M | $-90.55M |
| Short Term Investments | $189.41M | $195.99M | $190.98M | $168.53M | $127.09M | $155.60M | $222.40M | $220.85M | $246.40M | $264.10M | $250.48M | $245.17M | $233.16M | $239.33M | $184.76M | $218.57M | $189.96M | $135.98M | $103.94M | $181.10M |
| Cash and Short Term Investments | $244.90M | $255.64M | $264.10M | $258.19M | $253.68M | $216.57M | $286.70M | $305.03M | $276.15M | $313.65M | $307.78M | $291.17M | $309.28M | $402.07M | $465.91M | $313.48M | $371.69M | $199.41M | $216.09M | $90.55M |
| Net Receivables | $3.10M | $10.34M | $1.17M | $13.60M | $11.80M | $500.00K | $1.03M | $528.00K | $1.47M | $1.49M | $1.71M | $1.77M | $5.72M | $4.84M | $6.21M | $3.66M | $4.48M | $4.14M | $8.55M | $- |
| Inventory | $- | $- | $1 | $- | $- | $1 | $-19.41M | $-34.71M | $1 | $- | $- | $- | $- | $1 | $1 | $- | $- | $1 | $- | $- |
| Other Current Assets | $9.76M | $7.25M | $10.78M | $7.80M | $5.71M | $6.62M | $6.07M | $7.60M | $9.93M | $20.63M | $17.75M | $20.00M | $21.39M | $10.76M | $10.87M | $9.75M | $9.67M | $10.74M | $3.28M | $- |
| Total Current Assets | $257.77M | $273.23M | $276.04M | $279.59M | $271.19M | $223.69M | $274.39M | $278.45M | $287.56M | $325.46M | $318.37M | $302.95M | $325.69M | $412.29M | $477.56M | $322.01M | $381.01M | $208.92M | $227.92M | $90.55M |
| Property Plant Equipment Net | $63.38M | $65.37M | $67.35M | $69.13M | $71.09M | $72.81M | $74.64M | $76.24M | $77.52M | $79.03M | $79.46M | $77.85M | $35.05M | $15.57M | $16.23M | $16.92M | $16.55M | $17.12M | $17.57M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $22.36M | $- | $35.08M | $44.42M | $31.45M | $29.86M | $19.41M | $34.71M | $60.96M | $52.36M | $90.06M | $130.48M | $142.20M | $78.19M | $32.77M | $32.49M | $189.96M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $6.10M | $37.46M | $2.62M | $5.23M | $2.72M | $6.66M | $6.57M | $6.64M | $4.80M | $4.59M | $4.59M | $4.21M | $3.82M | $1.85M | $1.85M | $2.58M | $-187.38M | $3.08M | $2.58M | $-90.55M |
| Total Non-Current Assets | $91.83M | $102.83M | $105.05M | $118.78M | $105.26M | $109.33M | $100.62M | $117.58M | $143.28M | $135.98M | $174.11M | $212.54M | $181.08M | $95.62M | $50.86M | $52.00M | $19.13M | $20.20M | $20.15M | $-90.55M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.00K | $- | $- |
| Total Assets | $349.60M | $376.06M | $381.09M | $398.37M | $376.45M | $333.01M | $375.01M | $396.04M | $430.84M | $461.44M | $492.48M | $515.49M | $506.76M | $507.91M | $528.42M | $374.01M | $400.14M | $229.13M | $248.07M | $- |
| Account Payables | $1.33M | $1.50M | $913.00K | $1.63M | $1.45M | $1.28M | $2.25M | $1.03M | $1.17M | $2.37M | $4.45M | $3.40M | $4.51M | $3.75M | $4.47M | $3.74M | $5.68M | $5.26M | $5.86M | $- |
| Short Term Debt | $5.77M | $11.26M | $10.99M | $5.36M | $10.44M | $10.17M | $20.25M | $7.11M | $11.69M | $11.40M | $4.40M | $4.20M | $1.33M | $2.35M | $2.26M | $2.17M | $1.04M | $2.00M | $959.00K | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $18.71M | $20.77M | $36.59M | $35.14M | $15.47M | $8.42M | $38.62M | $30.78M | $16.62M | $18.13M | $22.17M | $31.27M | $31.80M | $32.29M | $28.70M | $26.57M | $27.60M | $23.91M | $22.16M | $- |
| Other Current Liabilities | $19.36M | $9.76M | $5.71M | $12.89M | $15.41M | $10.40M | $11.77M | $16.30M | $15.07M | $13.36M | $15.13M | $8.11M | $13.61M | $10.29M | $8.74M | $5.17M | $9.52M | $8.83M | $6.13M | $- |
| Total Current Liabilities | $45.18M | $43.29M | $54.20M | $55.02M | $42.77M | $30.27M | $48.24M | $39.38M | $44.55M | $45.27M | $46.15M | $46.99M | $51.25M | $48.69M | $44.17M | $37.65M | $43.85M | $40.01M | $35.11M | $- |
| Long Term Debt | $59.98M | $61.46M | $125.85M | $64.36M | $131.51M | $134.19M | $136.83M | $78.34M | $80.17M | $153.40M | $157.11M | $159.70M | $41.55M | $32.43M | $32.87M | $21.76M | $21.88M | $34.07M | $22.04M | $- |
| Deferred Revenue Non-Current | $28.46M | $28.65M | $16.91M | $20.71M | $21.81M | $19.62M | $24.65M | $15.85M | $16.89M | $16.77M | $17.99M | $19.02M | $24.37M | $38.94M | $46.19M | $50.89M | $53.62M | $61.08M | $67.14M | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $-16.91M | $-20.71M | $-21.81M | $-19.62M | $-24.65M | $8.62M | $9.20M | $9.05M | $10.37M | $-19.02M | $-24.37M | $-38.94M | $-46.19M | $-50.89M | $-11.83M | $-12.10M | $-12.36M | $- |
| Other Non-Current Liabilities | $- | $- | $-62.92M | $- | $-65.76M | $-67.09M | $-68.42M | $- | $- | $-72.18M | $-73.37M | $-74.75M | $- | $-10.92M | $-11.23M | $- | $- | $-6.63M | $- | $- |
| Total Non-Current Liabilities | $88.44M | $90.11M | $79.83M | $85.07M | $87.57M | $86.72M | $93.06M | $94.19M | $97.06M | $97.99M | $101.73M | $103.97M | $65.91M | $60.44M | $67.83M | $72.65M | $75.50M | $345.04M | $89.17M | $- |
| Other Liabilities | $- | $- | $- | $- | $-1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $133.62M | $133.40M | $134.03M | $140.09M | $130.34M | $116.99M | $141.30M | $133.57M | $141.61M | $143.26M | $147.88M | $150.96M | $117.16M | $109.13M | $111.99M | $110.30M | $119.35M | $385.05M | $124.29M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.00M | $252.02M | $111.00M |
| Common Stock | $7.00K | $7.00K | $7.00K | $7.00K | $6.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $4.00K | $4.00K | $1.00K | $4.00K | $- |
| Retained Earnings | $-633.70M | $-599.13M | $-574.46M | $-556.74M | $-528.38M | $-493.63M | $-466.59M | $-430.67M | $-395.89M | $-358.70M | $-326.75M | $-299.33M | $-267.71M | $-252.06M | $-227.37M | $-204.79M | $-183.82M | $-162.03M | $-140.19M | $- |
| Accumulated Other Comprehensive Income Loss | $53.00K | $455.00K | $-440.00K | $-380.00K | $-127.00K | $-904.00K | $-1.77M | $-2.47M | $-4.14M | $-5.41M | $-4.58M | $-3.65M | $-775.00K | $-155.00K | $-69.00K | $-94.00K | $13.00K | $8.00K | $-2.00K | $-111.96M |
| Other Total Stockholders Equity | $849.62M | $841.32M | $821.95M | $815.40M | $774.62M | $710.55M | $702.07M | $695.61M | $689.26M | $682.29M | $675.92M | $667.51M | $658.09M | $650.99M | $643.87M | $468.59M | $464.60M | $1.00M | $263.97M | $- |
| Total Stockholders Equity | $215.99M | $242.66M | $247.06M | $258.28M | $246.11M | $216.02M | $233.71M | $262.47M | $289.23M | $318.18M | $344.59M | $364.53M | $389.61M | $398.78M | $416.43M | $263.70M | $280.79M | $-155.92M | $123.78M | $-968.00K |
| Total Equity | $215.99M | $242.66M | $247.06M | $258.28M | $246.11M | $216.02M | $233.71M | $262.47M | $289.23M | $318.18M | $344.59M | $364.53M | $389.61M | $398.78M | $416.43M | $263.70M | $280.79M | $-155.92M | $123.78M | $-968.00K |
| Total Liabilities and Stockholders Equity | $349.60M | $376.06M | $381.09M | $398.37M | $376.45M | $333.01M | $375.01M | $396.04M | $430.84M | $461.44M | $492.48M | $515.49M | $506.76M | $507.91M | $528.42M | $374.01M | $400.14M | $229.13M | $248.07M | $-968.00K |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $349.60M | $376.06M | $381.09M | $398.37M | $376.45M | $333.01M | $375.01M | $396.04M | $430.84M | $461.44M | $492.48M | $515.49M | $506.76M | $507.91M | $528.42M | $374.01M | $400.14M | $229.13M | $248.07M | $-968.00K |
| Total Investments | $211.76M | $195.99M | $226.06M | $212.95M | $158.54M | $155.60M | $222.40M | $220.85M | $307.36M | $316.46M | $340.54M | $375.65M | $375.36M | $317.52M | $217.53M | $251.06M | $379.92M | $135.98M | $103.94M | $181.10M |
| Total Debt | $65.76M | $67.09M | $68.42M | $69.72M | $70.98M | $72.18M | $83.71M | $85.45M | $87.15M | $88.06M | $86.32M | $87.42M | $42.88M | $22.68M | $22.77M | $22.85M | $22.92M | $22.97M | $22.99M | $- |
| Net Debt | $10.26M | $7.45M | $-4.70M | $-19.94M | $-55.61M | $11.21M | $38.83M | $35.98M | $57.40M | $38.50M | $29.02M | $41.42M | $-33.24M | $-140.06M | $-258.38M | $-72.06M | $-158.81M | $-40.46M | $-89.16M | $90.55M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-105.32M | $-132.49M | $-128.18M | $-83.89M | $-66.33M |
| Depreciation and Amortization | $1.82M | $1.88M | $1.68M | $1.49M | $1.62M |
| Deferred Income Tax | $- | $- | $- | $1.88M | $5.58M |
| Stock Based Compensation | $29.66M | $27.23M | $30.02M | $21.51M | $3.43M |
| Change in Working Capital | $7.65M | $-6.94M | $-16.78M | $-30.09M | $-13.18M |
| Accounts Receivables | $8.70M | $-10.33M | $4.24M | $-1.23M | $139.00K |
| Inventory | $- | $- | $- | $-2.63M | $-1.58M |
| Accounts Payables | $-119.00K | $273.00K | $-3.33M | $-1.18M | $467.00K |
| Other Working Capital | $-930.00K | $3.12M | $-17.69M | $-25.05M | $-12.20M |
| Other Non Cash Items | $1.03M | $3.48M | $7.32M | $2.13M | $1.63M |
| Net Cash Provided by Operating Activities | $-65.16M | $-106.84M | $-105.94M | $-86.97M | $-67.25M |
| Investments in Property Plant and Equipment | $-180.00K | $-1.71M | $-5.50M | $-1.28M | $-650.00K |
| Acquisitions Net | $- | $- | $-63.92M | $188.06M | $189.85M |
| Purchases of Investments | $-284.32M | $-129.90M | $-219.53M | $-537.74M | $-293.86M |
| Sales Maturities of Investments | $233.23M | $289.95M | $283.44M | $349.68M | $104.00M |
| Other Investing Activities | $- | $- | $63.92M | $-188.06M | $-189.85M |
| Net Cash Used for Investing Activities | $-51.27M | $158.35M | $58.42M | $-189.34M | $-190.50M |
| Debt Repayment | $- | $-12.50M | $- | $- | $11.97M |
| Common Stock Issued | $44.37M | $57.67M | $777.00K | $169.47M | $340.60M |
| Common Stock Repurchased | $-194.00K | $-110.00K | $- | $- | $-194.00K |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.16M | $426.00K | $1.15M | $1.94M | $-3.45M |
| Net Cash Used Provided by Financing Activities | $45.34M | $45.49M | $1.15M | $171.40M | $348.93M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-71.09M | $97.00M | $-46.37M | $-104.90M | $91.18M |
| Cash at End of Period | $58.94M | $130.03M | $33.03M | $79.40M | $184.30M |
| Cash at Beginning of Period | $130.03M | $33.03M | $79.40M | $184.30M | $93.13M |
| Operating Cash Flow | $-65.16M | $-106.84M | $-105.94M | $-86.97M | $-67.25M |
| Capital Expenditure | $-180.00K | $-1.71M | $-5.50M | $-1.28M | $-650.00K |
| Free Cash Flow | $-65.34M | $-108.55M | $-111.44M | $-88.24M | $-67.90M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-34.57M | $-24.67M | $-17.72M | $-28.36M | $-34.75M | $-27.04M | $-35.92M | $-34.78M | $-37.19M | $-31.96M | $-27.41M | $-31.62M | $-15.66M | $-24.68M | $-22.58M | $-20.97M | $-21.80M | $-21.84M | $-10.79M | $-11.91M |
| Depreciation and Amortization | $480.00K | $-2.73M | $2.04M | $2.03M | $1.69M | $447.00K | $458.00K | $545.00K | $521.00K | $415.00K | $435.00K | $305.00K | $323.00K | $330.00K | $388.00K | $451.00K | $365.00K | $420.00K | $416.00K | $416.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-20.87M | $-472.00K | $-1.08M | $- | $- | $- | $- | $- | $847.00K | $558.00K | $372.00K | $102.00K | $2.48M | $3.10M | $- | $- |
| Stock Based Compensation | $8.23M | $8.83M | $6.38M | $6.21M | $6.36M | $8.20M | $6.42M | $6.25M | $6.92M | $6.01M | $8.15M | $8.94M | $6.35M | $6.09M | $5.23M | $3.85M | $2.72M | $436.00K | $161.00K | $116.00K |
| Change in Working Capital | $7.42M | $-9.22M | $5.87M | $3.36M | $3.40M | $-13.50M | $9.38M | $-6.22M | $-660.00K | $-4.21M | $-5.67M | $-6.24M | $-18.15M | $-1.16M | $-1.92M | $-8.86M | $-5.81M | $2.92M | $-4.71M | $-5.58M |
| Accounts Receivables | $7.24M | $-9.17M | $12.43M | $-1.80M | $-11.30M | $528.00K | $-500.00K | $945.00K | $15.00K | $222.00K | $63.00K | $3.94M | $-871.00K | $1.37M | $-2.56M | $828.00K | $-343.00K | $4.41M | $-5.23M | $1.30M |
| Inventory | $- | $- | $- | $- | $1.66M | $-2.62M | $960.00K | $- | $- | $- | $- | $- | $-2.98M | $1.72M | $2.58M | $-3.96M | $-2.29M | $3.42M | $-917.00K | $-1.79M |
| Accounts Payables | $-176.00K | $590.00K | $-715.00K | $182.00K | $169.00K | $-837.00K | $1.08M | $-138.00K | $-1.08M | $-1.69M | $588.00K | $-1.15M | $760.00K | $-601.00K | $627.00K | $-1.97M | $599.00K | $-594.00K | $2.56M | $-2.10M |
| Other Working Capital | $360.00K | $-641.00K | $-5.85M | $4.97M | $14.53M | $-10.57M | $7.84M | $-7.03M | $401.00K | $-2.74M | $-6.32M | $-9.04M | $-15.06M | $-3.65M | $-2.57M | $-3.77M | $-3.78M | $-4.30M | $-1.12M | $-3.00M |
| Other Non Cash Items | $503.00K | $3.66M | $-2.80M | $10.53M | $20.16M | $1.65M | $1.75M | $1.08M | $1.28M | $1.72M | $2.30M | $2.02M | $614.00K | $513.00K | $505.00K | $502.00K | $497.00K | $511.00K | $327.00K | $298.00K |
| Net Cash Provided by Operating Activities | $-17.93M | $-24.13M | $-4.97M | $-18.12M | $-24.01M | $-30.71M | $-19.00M | $-33.12M | $-29.13M | $-28.02M | $-22.20M | $-26.60M | $-25.67M | $-18.36M | $-18.00M | $-24.93M | $-21.54M | $-14.45M | $-14.59M | $-16.67M |
| Investments in Property Plant and Equipment | $4.00K | $13.00K | $-197.00K | $- | $-157.00K | $-600.00K | $-362.00K | $-589.00K | $-1.49M | $-3.31M | $-529.00K | $-172.00K | $-109.00K | $- | $-747.00K | $-421.00K | $-291.00K | $-284.00K | $109.00K | $-184.00K |
| Acquisitions Net | $- | $- | $- | $- | $-32.10M | $-58.33M | $-15.51M | $-54.12M | $-10.77M | $-23.22M | $-33.76M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-40.78M | $-68.56M | $-67.22M | $-107.75M | $-37.88M | $-31.94M | $-48.64M | $-11.44M | $-56.29M | $-55.11M | $-31.91M | $-76.22M | $-145.42M | $-154.70M | $-61.32M | $-176.30M | $-157.93M | $-31.98M | $-103.94M | $- |
| Sales Maturities of Investments | $54.45M | $68.71M | $55.72M | $54.35M | $69.98M | $90.27M | $64.15M | $65.56M | $67.06M | $78.33M | $65.67M | $72.39M | $86.11M | $54.08M | $94.50M | $114.99M | $104.00M | $- | $- | $- |
| Other Investing Activities | $- | $- | $-11.51M | $-53.40M | $32.10M | $58.33M | $15.51M | $54.12M | $10.77M | $23.22M | $33.76M | $-3.83M | $-59.30M | $-100.63M | $33.18M | $-61.31M | $-1.00K | $1.00K | $-103.94M | $- |
| Net Cash Used for Investing Activities | $13.67M | $162.00K | $-11.71M | $-53.40M | $31.95M | $57.73M | $15.15M | $53.53M | $9.28M | $19.91M | $33.23M | $-4.00M | $-59.41M | $-100.63M | $32.43M | $-61.73M | $-54.22M | $-32.27M | $-103.83M | $-184.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $-11.00M | $-750.00K | $-750.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $10.28M | $135.00K | $34.09M | $57.67M | $- | $2.00K | $- | $777.00K | $211.00K | $259.00K | $260.00K | $2.80M | $-469.00K | $170.50M | $-148.00K | $339.83M | $4.50M | $- | $- |
| Common Stock Repurchased | $- | $-85.00K | $- | $-109.00K | $- | $-16.00K | $- | $-94.00K | $- | $- | $- | $- | $- | $- | $- | $- | $16.00K | $-86.00K | $-851.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $112.00K | $310.00K | $135.00K | $603.00K | $-1.00K | $263.00K | $4.00K | $160.00K | $47.00K | $361.00K | $259.00K | $480.00K | $466.00K | $1.05M | $170.50M | $-151.00K | $-145.80M | $-1.91M | $152.22M | $156.00K |
| Net Cash Used Provided by Financing Activities | $112.00K | $10.51M | $135.00K | $34.58M | $57.67M | $-10.75M | $-746.00K | $-684.00K | $47.00K | $361.00K | $259.00K | $480.00K | $466.00K | $584.00K | $170.50M | $-151.00K | $194.05M | $2.50M | $152.22M | $156.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $11.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-4.15M | $-10.02M | $-16.55M | $-36.93M | $65.62M | $16.27M | $-4.59M | $19.72M | $-19.80M | $-7.75M | $11.29M | $-30.12M | $-84.62M | $-118.40M | $184.93M | $-86.81M | $118.29M | $-44.22M | $33.80M | $-16.69M |
| Cash at End of Period | $58.94M | $63.09M | $73.11M | $89.66M | $126.59M | $64.42M | $48.16M | $52.76M | $33.03M | $52.83M | $60.58M | $49.28M | $79.40M | $164.02M | $282.42M | $97.49M | $184.30M | $66.01M | $110.23M | $76.43M |
| Cash at Beginning of Period | $63.09M | $73.11M | $89.66M | $126.59M | $60.97M | $48.16M | $52.76M | $33.03M | $52.83M | $60.58M | $49.28M | $79.40M | $164.02M | $282.42M | $97.49M | $184.30M | $66.01M | $110.23M | $76.43M | $93.13M |
| Operating Cash Flow | $-17.93M | $-24.13M | $-4.97M | $-18.12M | $-24.01M | $-30.71M | $-19.00M | $-33.12M | $-29.13M | $-28.02M | $-22.20M | $-26.60M | $-25.67M | $-18.36M | $-18.00M | $-24.93M | $-21.54M | $-14.45M | $-14.59M | $-16.67M |
| Capital Expenditure | $4.00K | $13.00K | $-197.00K | $- | $-157.00K | $-600.00K | $-362.00K | $-589.00K | $-1.49M | $-3.31M | $-529.00K | $-172.00K | $-109.00K | $- | $-747.00K | $-421.00K | $-291.00K | $-284.00K | $109.00K | $-184.00K |
| Free Cash Flow | $-17.93M | $-24.12M | $-5.17M | $-18.12M | $-24.17M | $-31.31M | $-19.36M | $-33.71M | $-30.62M | $-31.32M | $-22.72M | $-26.77M | $-25.78M | $-18.36M | $-18.75M | $-25.36M | $-21.83M | $-14.73M | $-14.48M | $-16.85M |
C4 Therapeutics Dividends
Explore C4 Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
C4 Therapeutics News
Read the latest news about C4 Therapeutics, including recent articles, headlines, and updates.
C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
C4 Therapeutics to Participate in Upcoming March Investor Conferences
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences.
Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now
C4 Therapeutics (CCCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director.
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 345,600 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on October 28, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its participation in the 7th Annual Targeted Protein Degradation & Induced Proximity Summit, to be held October 28-31, 2024, in Boston, MA. Four members of the company's leadership team will deliver oral presentations or participate on panels to demonstrate the company's expertise in designing and developing highly catalytic orally bioavailable degraders that have the potential to transform patients' lives.
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein Early Evidence of CFT1946 Monotherapy Anti-Tumor Activity in Patients Who Have Progressed on or After BRAF Inhibitor Therapies; Majority of Patients Demonstrated Tumor Reduction Across V600 Mutation Types CFT1946 Global Phase 1 Trial Continues to Enroll; Monotherapy and Combination Expansion Cohorts Advancing With Additional Data Expected in 2025 C4T To Host Webcast Today at 12:00 pm ET; Webcast Link Available Here WATERTOWN, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced initial clinical data from the ongoing clinical trial of CFT1946, an orally bioavailable small molecule degrader of BRAF V600 mutations in solid tumors.
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity Investor Webcast to be Held Friday, September 13, 2024 at 12:00 pm ET WATERTOWN, Mass., Sept. 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the abstract sharing clinical data from its ongoing Phase 1 clinical trial of CFT1946, a novel BiDAC™ degrader, in mutant BRAF V600 solid tumors, was released in conjunction with the ESMO Congress 2024 scheduled for September 13 – 17, 2024 in Barcelona, Spain.
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service.
C4 Therapeutics to Participate in Upcoming September Investor Conferences
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor conferences.
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Preliminary Monotherapy Data from the Ongoing CFT1946 Phase 1 Trial in BRAF V600X Solid Tumors to be Presented at ESMO Congress 2024; Initiated Monotherapy Expansion Cohort in Melanoma and Combination Cohort with Cetuximab in Colorectal Cancer
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13 – 17, 2024 in Barcelona, Spain.
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Protein Degradation (TPD) Day taking place virtually on July 15, 2024.
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform the Board to Lead C4T into Next Phase of Growth WATERTOWN, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced changes to its Board of Directors as part of the Company's aspiration to become a fully integrated biotechnology company.
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidomide (CFT7455) and CFT1946; Data from Both Trials Expected in 2H 2024 Cash, Cash Equivalents and Marketable Securities Total $299.2 Million as of March 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the first quarter ended March 31, 2024, as well as recent business highlights.
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the Stifel 2024 Targeted Oncology Forum taking place virtually from April 16 – April 17, 2024.
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the American Association for Cancer Research (AACR) Annual Meeting 2024 highlighting new preclinical data for CFT1946 across multiple models of BRAF V600X mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), additional BRAF inhibitor (BRAFi)-resistant melanoma models, and an intracranial model of BRAF V600E metastatic melanoma.
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CCCC.